Mitochondrial Dysfunction and Insulin Resistance: Which Comes First?

Key Takeaways

• Mitochondrial dysfunction and insulin resistance form a bidirectional, self-reinforcing cycle - neither is reliably "first."
• Shared drivers include impaired fatty-acid oxidation, excess reactive oxygen species, defective mitophagy, and chronic low-grade inflammation.
• Insulin resistance and poor metabolic health may be among the most important biomarkers of overall health status, influencing the risk of obesity, cardiovascular disease, chronic kidney disease, fatty liver disease, cognitive decline, ocular complications, and accelerated aging.
• Metabolic flexibility - the efficient switching between glucose, fats, and ketones - is emerging as an earlier marker of dysfunction than mitochondrial content alone. Exercise, caloric moderation, and intermittent fasting remain the most powerful levers; targeted nutrients may add complementary support.
• Nutrients with mechanistic and emerging clinical rationale include CoQ10, alpha-lipoic acid, berberine, resveratrol, omega-3 fatty acids, and NAD+ precursors (NR, NMN).

One of the earliest and most influential hypotheses proposed that mitochondrial dysfunction directly contributes to insulin resistance by impairing fatty acid oxidation. When mitochondrial oxidative capacity is reduced, cells lose the ability to efficiently metabolize fatty acids. This leads to the buildup of intracellular lipid intermediates, including diacylglycerols (DAGs), ceramides, and long-chain acyl-CoAs. These metabolites activate stress-sensitive kinases such as protein kinase C (PKC), which interfere with insulin receptor signaling and reduce insulin-stimulated glucose uptake.

Supporting this hypothesis, Petersen et al. (2004) showed that insulin-resistant offspring of individuals with type 2 diabetes exhibited reduced mitochondrial ATP synthesis and increased intramyocellular lipid accumulation, even before the onset of overt diabetes.

Mitochondrial dysfunction can also impair insulin sensitivity through excessive production of reactive oxygen species. Although physiological levels of ROS serve important signaling functions, excessive ROS damages proteins, lipids, and nucleic acids while disrupting insulin signaling pathways. Oxidative stress inhibits insulin receptor substrate (IRS)-mediated activation of phosphatidylinositol 3-kinase (PI3K) and Akt, both critical mediators of insulin action. Elevated ROS also activates inflammatory pathways such as nuclear factor-kappa B (NF-κB) and c-Jun N-terminal kinase (JNK), both of which have been strongly implicated in insulin resistance (Lowell and Shulman, 2005).

Another important mechanism involves impaired mitochondrial biogenesis. Reduced expression of key regulators such as PGC-1α, NRF1, NRF2, and TFAM has been observed in insulin-resistant skeletal muscle. Diminished mitochondrial biogenesis limits oxidative metabolism, reduces ATP production, and impairs metabolic flexibility, ultimately promoting insulin resistance and the progression of metabolic disease (Montgomery and Turner, 2015).

Recent research has broadened the conversation beyond mitochondrial quantity and oxidative capacity to include metabolic flexibility, the ability of cells to switch efficiently between glucose, fatty acid, and ketone metabolism depending on nutrient availability. Healthy mitochondria continually adjust substrate utilization to maintain energy homeostasis. Insulin-resistant tissues, however, lose this adaptability and become metabolically inflexible.

This loss of flexibility leads to inefficient fuel utilization, accumulation of metabolic intermediates, and increased mitochondrial stress. Emerging evidence suggests that metabolic inflexibility may occur before measurable reductions in mitochondrial content, which may help explain why some insulin-resistant individuals still appear to have normal mitochondrial abundance despite significant metabolic dysfunction. Recent studies further show that mitochondrial utilization of ketone bodies is diminished in obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease (MASLD), suggesting that impaired substrate switching may be a defining feature of early mitochondrial dysfunction (Veluthakal et al., 2024).

While substantial evidence supports a causal role for mitochondrial dysfunction, a growing body of research suggests the reverse may also be true. Chronic overnutrition exposes tissues to excessive glucose and fatty acids, initially promoting lipid accumulation and insulin resistance. Persistent hyperinsulinemia and nutrient overload then place additional stress on mitochondria, leading to increased ROS production, impaired oxidative phosphorylation, and structural damage.

In this model, insulin resistance precedes mitochondrial dysfunction. As insulin-resistant cells continue to receive excess nutrient inputs, mitochondrial respiratory systems become overwhelmed, leading to progressive bioenergetic decline. This perspective also helps explain observations that some individuals develop insulin resistance before any detectable mitochondrial defects emerge (Montgomery and Turner, 2015).

Insulin resistance is also associated with altered mitochondrial dynamics. Healthy mitochondrial networks continuously undergo fusion and fission processes that maintain integrity and function. Insulin-resistant tissues often show disruptions in these processes, leading to fragmented mitochondrial networks, reduced respiratory efficiency, and increased oxidative stress. Such alterations contribute to the progressive decline in mitochondrial health observed in obesity and type 2 diabetes.

One of the most significant advances in recent years has been the recognition that mitochondrial quality control may be just as important as mitochondrial bioenergetics in determining insulin sensitivity. Mitophagy, the selective removal of damaged mitochondria, is essential for maintaining a healthy mitochondrial network. When mitophagy becomes impaired, dysfunctional mitochondria accumulate, producing excessive ROS and inflammatory signals while generating less ATP.

Recent investigations indicate that defects in the PINK1-Parkin pathway, a major regulator of mitophagy, contribute to both aging and metabolic disease. Emerging evidence also suggests that glucose metabolism directly regulates mitophagy through nutrient-sensitive signaling pathways. Chronic hyperglycemia and nutrient overload can therefore impair mitochondrial turnover, creating a vicious cycle in which damaged mitochondria accumulate and further worsen insulin resistance (Chandrasekaran and Weiskirchen, 2024).

Historically, mitochondria were viewed primarily as the cell's power plants. Modern research, however, has revealed that mitochondria function as dynamic signaling hubs that communicate extensively with the endoplasmic reticulum, lysosomes, peroxisomes, and nucleus. This communication regulates calcium homeostasis, lipid metabolism, inflammation, nutrient sensing, and stress responses.

Disruptions in these communication networks are increasingly recognized as contributors to metabolic disease. For example, dysfunction of mitochondria-associated endoplasmic reticulum membranes (MAMs) can alter calcium signaling and lipid trafficking, promoting insulin resistance and inflammation. Similarly, impaired communication between mitochondria and lysosomes reduces autophagic clearance of damaged organelles, further compromising cellular health. These findings suggest that mitochondrial dysfunction should be viewed as a systems-level disturbance rather than an isolated organelle defect (Amorim et al., 2022; Zhang et al., 2024).

Recent evidence highlights chronic low-grade inflammation as a critical link between mitochondrial dysfunction and insulin resistance. Dysfunctional mitochondria release mitochondrial DNA, ROS, and other damage-associated molecular patterns (DAMPs) that activate innate immune pathways. These signals stimulate inflammatory cytokines that interfere with insulin receptor signaling and glucose metabolism.

Inflammation, in turn, further impairs mitochondrial function by increasing oxidative stress, disrupting mitochondrial dynamics, and suppressing mitochondrial biogenesis. This reciprocal interaction creates a self-amplifying cycle in which mitochondrial dysfunction promotes inflammation and inflammation further damages mitochondria. Such mechanisms may help explain why obesity, aging, metabolic syndrome, and type 2 diabetes share common inflammatory signatures despite differing initiating factors (James et al., 2021; Veluthakal et al., 2024).

Human studies investigating the relationship between mitochondrial dysfunction and insulin resistance have produced mixed results. Several investigations have reported reduced mitochondrial content, lower ATP synthesis rates, and impaired oxidative capacity in individuals who are insulin resistant or genetically predisposed to type 2 diabetes (Petersen et al., 2004). These findings support the view that mitochondrial defects can contribute to the early stages of metabolic disease.

Other studies, however, have challenged this interpretation. Holloszy (2009) argued that mitochondrial deficiency alone does not necessarily cause insulin resistance, noting that some individuals with reduced mitochondrial content still maintain normal insulin sensitivity. Improvements in insulin sensitivity also do not always correspond with increases in mitochondrial content or respiratory capacity. These observations suggest that mitochondrial dysfunction is neither universally necessary nor sufficient for insulin resistance, and that multiple interacting pathways contribute to disease development.

Given the evidence supporting both perspectives, many investigators now favor a bidirectional model. In this framework, chronic overnutrition and sedentary behavior raise circulating glucose and fatty acids, leading to intracellular lipid accumulation. These lipid metabolites interfere with insulin signaling and initiate insulin resistance. As insulin resistance progresses, mitochondrial stress builds through nutrient overload, oxidative damage, altered mitochondrial dynamics, and impaired mitophagy. Dysfunctional mitochondria then generate additional ROS, inflammatory mediators, and metabolic abnormalities that further worsen insulin resistance.

Rather than a linear sequence of events, mitochondrial dysfunction and insulin resistance appear to evolve together in a self-reinforcing cycle. This cycle contributes to the development and progression of type 2 diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD), cardiovascular disease, and numerous age-related disorders (Lowell and Shulman, 2005; Montgomery and Turner, 2015; Veluthakal et al., 2024).

Mitochondrial dysfunction and insulin resistance are increasingly recognized as hallmarks of biological aging. Aging is associated with reduced mitochondrial biogenesis, impaired oxidative phosphorylation, increased oxidative stress, and diminished mitochondrial quality control. At the same time, age-related insulin resistance promotes chronic inflammation, altered nutrient sensing, impaired autophagy, and cellular senescence.

Senescent cells exhibit profound mitochondrial abnormalities, including impaired respiration, altered dynamics, and excessive ROS production. They also secrete pro-inflammatory factors collectively known as the senescence-associated secretory phenotype (SASP), which further impairs insulin signaling in surrounding tissues. As a result, mitochondrial dysfunction and cellular senescence reinforce one another, accelerating age-related decline (Amorim et al., 2022).

Recent studies suggest that restoring mitochondrial quality control may reverse certain aspects of cellular aging. Interventions that stimulate mitophagy, enhance mitochondrial biogenesis, or improve mitochondrial substrate utilization have shown beneficial effects on metabolic health and inflammatory burden. Bharath et al. (2020) further demonstrated that enhancing autophagy and restoring mitochondrial function can alleviate aging-associated inflammation, highlighting the therapeutic potential of targeting mitochondrial health.

Given the central role of mitochondrial dysfunction and insulin resistance in metabolic disease and aging, considerable attention has been directed toward dietary supplements that target both processes simultaneously. Several naturally occurring bioactive compounds have demonstrated the ability to enhance mitochondrial biogenesis, improve oxidative phosphorylation, reduce oxidative stress, activate cellular energy-sensing pathways, and improve insulin signaling. Among the most extensively studied compounds are coenzyme Q10 (CoQ10), alpha-lipoic acid (ALA), acetyl-L-carnitine, nicotinamide adenine dinucleotide (NAD+) precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), berberine, resveratrol, omega-3 fatty acids, and polyphenol-rich botanical extracts. These compounds exert their beneficial effects through multiple mechanisms, including activation of AMP-activated protein kinase (AMPK), stimulation of sirtuin signaling pathways, enhancement of mitochondrial biogenesis through PGC-1α activation, reduction of mitochondrial reactive oxygen species production, and improvement of mitochondrial quality-control mechanisms such as mitophagy (Wu et al., 2024; Utami et al., 2023; Amorim et al., 2022; Capece et al., 2022; Dludla et al., 2020).

Among these interventions, berberine has attracted significant attention because of its ability to activate AMPK, a key cellular energy sensor that regulates glucose uptake, fatty acid oxidation, and mitochondrial biogenesis. Several clinical and preclinical studies have shown that berberine improves insulin sensitivity, lowers blood glucose levels, and enhances mitochondrial function in metabolic tissues (Utami et al., 2023). Similarly, resveratrol, a polyphenolic compound found in grapes and berries, has been shown to activate sirtuin-1 (SIRT1) and PGC-1α signaling pathways, thereby promoting mitochondrial biogenesis and improving metabolic flexibility (Wu et al., 2024). Coenzyme Q10, an essential component of the mitochondrial electron transport chain, has demonstrated benefits in improving mitochondrial bioenergetics and reducing oxidative stress, particularly in individuals with metabolic syndrome and type 2 diabetes (Dludla et al., 2020). Alpha-lipoic acid, a potent mitochondrial antioxidant and metabolic cofactor, has been reported to improve insulin-stimulated glucose disposal while simultaneously reducing oxidative stress and inflammation (Capece et al., 2022).

More recently, interest has expanded toward NAD+ restoration strategies because declining cellular NAD+ levels are increasingly recognized as a hallmark of aging and mitochondrial dysfunction. NAD+ serves as a critical cofactor for mitochondrial energy metabolism and sirtuin activity. Supplementation with NAD+ precursors such as nicotinamide riboside and nicotinamide mononucleotide has been shown in experimental models to improve mitochondrial function, enhance oxidative metabolism, stimulate mitophagy, and improve insulin sensitivity. Although large-scale human clinical trials are still ongoing, early findings suggest that restoring NAD+ availability may help counteract age-related declines in mitochondrial health and metabolic function. Likewise, omega-3 fatty acids have been shown to improve mitochondrial membrane composition, reduce inflammation, enhance fatty acid oxidation, and improve insulin signaling, further supporting their potential role in metabolic health promotion (Veluthakal et al., 2024; Jerab et al., 2025).

Importantly, dietary supplements should not be viewed as substitutes for foundational lifestyle practices. While targeted nutrients may support mitochondrial function and insulin sensitivity, the strongest evidence continues to support lifestyle interventions as the primary drivers of metabolic health. Regular physical activity, including achieving approximately 8,000-10,000 steps per day, structured exercise, adequate sunlight exposure to support circadian rhythm regulation, restorative sleep, stress management, and consumption of a nutrient-dense whole-food diet all exert profound effects on mitochondrial function and insulin signaling. These simple lifestyle practices improve metabolic flexibility, reduce inflammation, enhance mitochondrial quality control, and promote long-term metabolic resilience. Nutritional supplementation may provide complementary benefits, but optimal results are achieved when supplements are combined with these fundamental lifestyle behaviors.

Although insulin resistance is often discussed primarily in the context of type 2 diabetes, its effects extend far beyond glucose regulation. Insulin resistance contributes to systemic inflammation, endothelial dysfunction, impaired mitochondrial function, altered lipid metabolism, and abnormal nutrient sensing. Over time, these disturbances increase the risk of chronic kidney disease, cardiovascular disease, obesity, fatty liver disease, ocular complications, neurodegenerative disorders, and other age-associated conditions. Because insulin signaling influences nearly every organ system, improving insulin sensitivity may provide benefits that extend well beyond glycemic control (Beale EG., 2013).

From a public health perspective, addressing insulin resistance may represent one of the most effective strategies for reducing chronic disease burden in populations consuming a modern Western diet characterized by excess calories, ultra-processed foods, sedentary behavior, chronic stress, and insufficient sleep. Improving metabolic health has the potential to simultaneously reduce multiple chronic disease risks while enhancing both longevity and quality of life (Alyafei et al, 2025).

The traditional debate over whether mitochondrial dysfunction or insulin resistance comes first is gradually evolving into a broader understanding of metabolic network dysfunction. Current evidence suggests that nutrient overload, impaired metabolic flexibility, defective mitophagy, chronic inflammation, altered mitochondrial communication, and cellular senescence all contribute to the progressive deterioration of both mitochondrial function and insulin sensitivity.

This evolving paradigm has important implications for longevity science. Lifestyle interventions such as exercise, caloric restriction, and intermittent fasting, along with emerging therapies targeting NAD+ metabolism, AMPK activation, mitochondrial quality control, and senescent cell clearance, may simultaneously improve mitochondrial function and insulin sensitivity. Rather than focusing on a single pathway, future therapeutic strategies may need to address the interconnected network linking mitochondrial dysfunction, inflammation, aging, and metabolic disease.

The longstanding debate over whether mitochondrial dysfunction or insulin resistance develops first is becoming less important than understanding how these processes interact to drive chronic disease. Accumulating evidence suggests that both are components of a self-reinforcing cycle that progressively impairs metabolic health, accelerates biological aging, and increases susceptibility to numerous chronic diseases.

Perhaps more importantly, insulin resistance should be viewed as one of the most significant biomarkers of overall health status in modern populations. Poor metabolic health contributes to a cascade of downstream conditions including obesity, cardiovascular disease, chronic kidney disease, fatty liver disease, cognitive decline, ocular health disorders, and other age-related diseases. As a result, interventions that improve insulin sensitivity and metabolic flexibility have the potential to generate broad health benefits across multiple organ systems simultaneously.

The encouraging reality is that many of the most effective interventions remain remarkably simple. Regular physical activity, maintaining a healthy body composition, achieving adequate sleep, obtaining regular sunlight exposure, reducing consumption of ultra-processed foods, practicing caloric moderation, and incorporating evidence-based nutritional support can significantly improve metabolic health. By interrupting the vicious cycle connecting insulin resistance and mitochondrial dysfunction, individuals may substantially reduce their risk of chronic disease while improving both lifespan and healthspan.

This perspective shifts the focus away from determining which abnormality occurs first and toward addressing the underlying metabolic dysfunction that fuels both. Successfully targeting this interconnected network may represent one of the most powerful strategies available today for preventing chronic disease, extending healthspan, and promoting healthy aging throughout the lifespan.